These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3437498)

  • 1. Pharmacokinetics of propafenone in the dog after single-dose intravenous administration.
    Puigdemont A; Lligoña LL; Arboix M; de Mora F; Fernandez J
    J Vet Pharmacol Ther; 1987 Dec; 10(4):351-3. PubMed ID: 3437498
    [No Abstract]   [Full Text] [Related]  

  • 2. Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models.
    Puigdemont A; Riu JL; Guitart R; Arboix M
    J Pharmacol Methods; 1990 Apr; 23(2):79-85. PubMed ID: 2332982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of an extemporaneous suspension of propafenone made from tablets.
    Olguín HJ; Pérez CF; Pérez JF; Mendiola BR; Portugal MC; Chávez JB
    Biopharm Drug Dispos; 2006 Jul; 27(5):241-5. PubMed ID: 16586461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution of propafenone in the rat after intravenous administration.
    Fernández J; Lligoña L; Puigdemont A; Guitart R; Riu JL; Arboix M
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):23-7. PubMed ID: 1936057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodialysis removal of propafenone.
    Burgess ED; Duff HJ
    Pharmacotherapy; 1989; 9(5):331-3. PubMed ID: 2813154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of hepatic dysfunction on the pharmacokinetics of propafenone.
    Lee JT; Yee YG; Dorian P; Kates RE
    J Clin Pharmacol; 1987; 27(5):384-9. PubMed ID: 3693582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of propafenone enantiomers in rats.
    Mehvar R
    Drug Metab Dispos; 1990; 18(6):987-91. PubMed ID: 1981549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.
    Ito S; Gow R; Verjee Z; Giesbrecht E; Dodo H; Freedom R; Tonn GR; Axelson JE; Zalzstein E; Rosenberg HC; Koren G
    J Clin Pharmacol; 1998 Jun; 38(6):496-501. PubMed ID: 9650538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia.
    Gillis AM; Wyse DG; Mitchell LB; Duff HJ
    Am J Cardiol; 1996 Sep; 78(5):579-81. PubMed ID: 8806349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy.
    Capucci A; Boriani G; Marchesini B; Strocchi E; Tomasi L; Balducelli M; Frabetti L; Ambrosioni E; Magnani B
    Cardiovasc Drugs Ther; 1990 Feb; 4(1):281-7. PubMed ID: 2285622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacodynamic effects of intravenous and oral propafenone.
    Haefeli EW; Vozeh S; Ha HR; Follath F
    Clin Pharmacol Ther; 1990 Sep; 48(3):245-54. PubMed ID: 2401123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of intravenous propafenone on the internal ventricular defibrillation threshold in the anesthetized dog.
    Peters W; Gang ES; Okazaki H; Solingen S; Kobayashi Y; Karagueuzian HS; Mandel WJ
    Am Heart J; 1991 Nov; 122(5):1355-60. PubMed ID: 1951000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonlinear kinetics of propafenone metabolites in healthy man.
    Vozeh S; Haefeli W; Ha HR; Vlcek J; Follath F
    Eur J Clin Pharmacol; 1990; 38(5):509-13. PubMed ID: 2379537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological cardioversion of atrial fibrillation with intravenous and oral propafenone].
    Peciuliene I; Lukoseviciūte A
    Medicina (Kaunas); 2002; 38(12):1212-6. PubMed ID: 12552163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
    Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
    Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone.
    Dilger K; Hofmann U; Klotz U
    Clin Pharmacol Ther; 2000 May; 67(5):512-20. PubMed ID: 10824630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog.
    Boucher M; Chassaing C; Hamel JD; Poirier JM
    Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans.
    Sasaki S; Koumi S; Sato R; Murata M; Nagasawa K; Sakurai E; Hikichi N; Hayakawa H
    Gen Pharmacol; 1998 Oct; 31(4):589-91. PubMed ID: 9792220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HPLC determination of diprafenone and its active metabolite 5-hydroxydiprafenone in human plasma].
    Zhong D; Blume H
    Pharmazie; 1994 Jan; 49(1):38-41. PubMed ID: 8140128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.